Fibrinogen Blood Test: Clotting, Inflammation and Cardiovascular Risk

What Is Fibrinogen?

Fibrinogen (also called Factor I) is a large glycoprotein produced by the liver and released into the bloodstream at all times. When a blood vessel is damaged, thrombin cleaves fibrinogen into fibrin — the structural protein that forms the mesh of a blood clot. Without adequate fibrinogen, blood cannot clot properly. With too much, blood is hypercoagulable and clots form too readily in intact vessels.

Beyond clotting, fibrinogen plays a role in inflammation, platelet aggregation, cell adhesion, and the viscosity of blood. It is classified as an acute-phase reactant, meaning liver production increases in response to tissue injury, infection, and inflammatory cytokines — particularly IL-6. This makes fibrinogen both a clotting marker and an inflammation marker.

Fibrinogen Reference Ranges

Category	Fibrinogen Level (g/L)	What It Suggests
Optimal (lowest CV risk)	1.5–2.5	Normal clotting ability, low inflammatory burden
Normal lab range	2.0–4.0	Within standard reference range
Elevated	4.0–6.0	Increased clotting risk; investigate cause
High (significant risk)	>6.0	Hypercoagulable state; active inflammation or disease
Low (bleeding risk)	<1.5	Impaired clot formation; investigate cause

Note that fibrinogen naturally rises during pregnancy (it can reach 6–7 g/L at term), with acute illness, after surgery, and in smokers. These situational elevations should be distinguished from chronically elevated baseline levels, which carry long-term cardiovascular risk.

Fibrinogen and Cardiovascular Disease

The Fibrinogen Studies Collaboration — a meta-analysis of over 150,000 people — found that fibrinogen in the top third of the population has approximately twice the cardiovascular mortality risk compared to those in the bottom third, independent of blood pressure, cholesterol, smoking, and diabetes.

The mechanisms are multiple. High fibrinogen increases blood viscosity, making the heart work harder. It promotes platelet aggregation, increasing the risk of clots forming on atheromatous plaques. Fibrinogen also directly contributes to plaque formation by depositing fibrin into arterial walls. Together, these effects make high fibrinogen a meaningful addition to standard cardiovascular risk assessment.

What Causes High Fibrinogen?

Since fibrinogen is an acute-phase reactant, any cause of systemic inflammation can raise it. Chronic causes of persistently elevated fibrinogen include smoking (one of the most potent elevators), obesity and metabolic syndrome, type 2 diabetes and insulin resistance, chronic infections (including H. pylori and periodontal disease), autoimmune conditions such as rheumatoid arthritis and lupus, and chronic kidney disease.

Certain medications also raise fibrinogen — particularly oestrogen-containing contraceptives and hormone replacement therapy. Pregnancy, as noted, produces a physiological rise. Genetic variants affecting the fibrinogen genes (FGA, FGB, FGG) explain some of the heritable variation in baseline levels.

Low Fibrinogen: When Clotting Is Impaired

Low fibrinogen (<1.5 g/L) is less common than elevated levels and primarily indicates a bleeding risk. Causes include liver disease (where fibrinogen production is impaired), disseminated intravascular coagulation (DIC — a life-threatening condition where clotting factors are consumed faster than they can be replaced), congenital afibrinogenaemia (rare), and the use of thrombolytic drugs used to dissolve clots in stroke or heart attack treatment.

Fibrinogen vs CRP: What Each Test Adds

Both fibrinogen and CRP are acute-phase reactants that rise with inflammation. However, they are regulated by different pathways and respond with different time courses. CRP rises within hours of an inflammatory stimulus and falls quickly. Fibrinogen rises more slowly and stays elevated longer — it better reflects chronic, low-grade inflammation rather than acute spikes.

In cardiovascular risk assessment, fibrinogen adds information over and above CRP, and vice versa. Having both elevated independently predicts higher risk than either alone. For routine risk assessment, high-sensitivity CRP (hsCRP) is more widely ordered; fibrinogen is typically requested when a more complete haemostatic profile is needed or in assessment of hypercoagulable states.

How to Lower High Fibrinogen

The most effective strategies target the underlying causes. Smoking cessation produces some of the largest reductions in fibrinogen — smoking raises fibrinogen by 0.3–0.5 g/L on average. Weight loss in people with obesity consistently lowers fibrinogen in proportion to fat mass lost. Regular aerobic exercise independently reduces fibrinogen levels. Treating chronic infections and inflammatory conditions (periodontal disease, H. pylori, autoimmune flares) also brings fibrinogen down.

Dietary factors with evidence for reducing fibrinogen include omega-3 fatty acids (fish oil), moderate alcohol consumption (which reduces blood viscosity and fibrinogen, though this does not outweigh harms at higher intake), and high-fibre diets. Medications that lower fibrinogen include fibrates (used for hypertriglyceridaemia) and statins (modest effect).